Sign In
Buy AVRO
$1.40
+0 (+0%)
At Close: Sep 19, 2024
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
AVROBIO (AVRO) Presents At 18th Annual Global Healthcare Virtual Conference - Slideshow
01:51pm, Monday, 14'th Sep 2020
The following slide deck was published by AVROBIO, Inc. in conjunction with this event..
AVROBIO (AVRO) Investor Presentation - Slideshow
10:56am, Friday, 11'th Sep 2020
The following slide deck was published by AVROBIO, Inc. in conjunction with this event..
Restaurant chain Chilango sold in deal that safeguards 130 jobs
12:47pm, Thursday, 27'th Aug 2020
A rescue deal for restaurant chain Chilango has been agreed in a sale that involves most of the estate remaining open. Investment group RD Capital Partners (RDCP), run by founders Sameer Rizvi and Iry
AVROBIO (AVRO) Presents At 2020 Wedbush PacGrow Healthcare Conference - Slideshow
06:02pm, Thursday, 13'th Aug 2020
The following slide deck was published by AVROBIO, Inc. in conjunction with this event..
Did Hedge Funds Make The Right Call On AVROBIO, Inc. (AVRO) ?
01:41pm, Wednesday, 12'th Aug 2020
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Friday, 07'th Aug 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00am, Friday, 07'th Aug 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
11:00am, Thursday, 06'th Aug 2020
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter end
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
12:00am, Thursday, 06'th Aug 2020
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to
AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
11:00am, Wednesday, 05'th Aug 2020
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO,
Head-To-Head Analysis: Avrobio (NASDAQ:AVRO) and Cellectis (NASDAQ:CLLS)
01:36am, Monday, 03'rd Aug 2020
Avrobio (NASDAQ:AVRO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends,
AVROBIO Sees Hammer Chart Pattern: Time to Buy?
12:23pm, Monday, 27'th Jul 2020
AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Wednesday, 08'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00am, Wednesday, 08'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
